## SYK: Stryker Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.9% below STRENGTH zone (3.0-6.0%); PEG 1.45 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($337.71)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Stryker to Release Fourth Quarter and Full Year 2025 Financial Results on January 29, 2026**
- Source: Quiver Quantitative | 20260105T131900 | Neutral | Relevance: 100%
- Stryker (NYSE: SYK) will announce its fourth quarter and full year 2025 financial results on January 29, 2026, via a press release at approximately 4:05 p.m. ET, followed by a webcast at 4:30 p.m. ET to discuss these results. The company, a global leader in medical technology, will provide summary financial information for the periods ending December 31, 2025. This release aims to provide transparency to investors and highlight Stryker's ongoing commitment to improving healthcare outcomes.

**2. Robert Cohen of Stryker Named Chair of AdvaMed’s Digital Health Tech Division Board of Directors**
- Source: WebWire | 20260105T170551 | Bullish | Relevance: 100%
- Robert Cohen, Vice President of Innovation and Technology at Stryker, has been appointed as the new chair of AdvaMed's Digital Health Tech Board of Directors, succeeding Dr. Taha Kass-Hout. AdvaMed, the Medtech Association, highlights the increasing focus on digital health tech in policy discussions aimed at improving personalized care, patient outcomes, and healthcare affordability. Cohen will serve a two-year term, focusing on advancing digital health to transform patient care and ensure policies support the future of healthcare.

**3. Capital Advisors Inc. OK Grows Stock Holdings in Stryker Corporation $SYK**
- Source: MarketBeat | 20260104T095341 | Bullish | Relevance: 100%
- Capital Advisors Inc. OK has increased its stake in Stryker Corporation by 6.0% in Q3, now owning 164,288 shares worth approximately $60.73 million. This increase in institutional ownership comes despite significant insider selling, with executives disposing of shares worth $185.38 million in the last quarter. Stryker recently beat Q3 earnings expectations and raised its quarterly dividend, signaling continued financial health.

**4. Stryker Corp. stock: quiet chart, firm pulse – is this medtech leader still a buy after its latest run?**
- Source: AD HOC NEWS | 20260103T170828 | Bullish | Relevance: 100%
- Stryker Corp. stock is showing a quiet trading period after a strong rally, leading analysts and investors to reassess its growth potential. Despite this calm, the company maintains a bullish outlook supported by solid earnings, resilient procedure volumes, and positive analyst ratings. The question now revolves around how much upside remains for this medtech leader, which continues to outperform broader healthcare benchmarks.

**5. Stryker to announce financial results for its fourth quarter and full year 2025**
- Source: GlobeNewswire | 20260105T080000 | Neutral | Relevance: 94%
- Stryker (NYSE: SYK) will announce its financial results for the fourth quarter and full year 2025 on Thursday, January 29, 2026. A press release will be issued at approximately 4:05 p.m. ET, followed by a webcast at 4:30 p.m. ET to discuss the results.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-19 | Citizens | $440 | $0 | 0% |
| 2025-12-18 | Truist Securiti | $392 | $400 | -2% |
| 2025-12-11 | Citigroup | $420 | $455 | -8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-19 | Citizens | up | Market Outperform |
| 2025-12-18 | Truist Securiti | main | Hold |
| 2025-12-11 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.76M) |
| Sells | 7 ($21.05M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (+0.8%)
- Blackrock Inc.: 7.0% (+0.4%)
- JPMORGAN CHASE & CO: 6.2% (+95.3%)
- Greenleaf Trust: 4.3% (-0.3%)
- State Street Corpora: 3.9% (-0.1%)

### Key Risks

1. Heavy insider selling: $21M sold (7 transactions in 90 days).
2. Long-term trend broken: trading 6.9% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.45 suggests fair value with growth premium. Forward P/E 23.3x stretched relative to 10% growth. Balance sheet: $1.4B free cash flow. Analyst sentiment negative (2 target cuts vs 0 raises). Insider selling cluster ($21.1M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $133.4B |
| Beta | 0.90 |
| 52W Range | $329.16 - $406.19 |
| Short Interest | 1.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.45 |
| Forward P/E | 23.3 |
| Current P/E | 25.7 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at -0.9% (minimal 5-day change). Below STRENGTH zone by 3.9pp (needs >3.0% for momentum thesis). Below SMA200 (0.93x), long-term trend not supportive. OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.91% (CS: 25) | Neutral |
| RSI_14 | 37.3 | Neutral |
| MACD Histogram | -0.17 | Bearish |
| vs SMA20 | 0.986x | Below |
| vs SMA50 | 0.965x | Below |
| vs SMA200 | 0.931x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $348.75
- **Stop Loss:** $337.71 (3.2% risk)
- **Target:** $359.79 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 78
- **Position Value:** $27,202.50
- **Portfolio %:** 27.20%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-01-27 (Est: $4.39)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.13 | $3.19 | +1.9% |
| 2025Q2 | $3.07 | $3.13 | +1.9% |
| 2025Q1 | $2.73 | $2.84 | +4.0% |
| 2024Q4 | $3.87 | $4.01 | +3.5% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_10*